• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 4. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 5. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361

• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues Purine nucleosides Purine 2'-deoxyribonucleosides

Introduction to N6-(6-Aminohexyl)-2’-deoxyadenosine (CAS No. 147218-60-8)

N6-(6-Aminohexyl)-2’-deoxyadenosine, a compound with the chemical identifier CAS No. 147218-60-8, represents a significant advancement in the field of nucleoside chemistry and its applications in biomedical research. This synthetic nucleoside derivative has garnered considerable attention due to its unique structural properties and potential therapeutic applications, particularly in the realm of drug development and molecular biology.

The molecular structure of N6-(6-Aminohexyl)-2’-deoxyadenosine features a modified adenosine backbone, where the 6-amino group is replaced with a 6-aminohexyl side chain. This modification enhances the compound's solubility and bioavailability, making it an attractive candidate for various pharmacological studies. The introduction of the long aliphatic chain not only improves its pharmacokinetic profile but also allows for targeted delivery systems, which could be pivotal in developing novel treatments for diseases such as cancer, neurodegenerative disorders, and infectious diseases.

Recent research has highlighted the compound's potential as an antagonist of adenosine receptors. Adenosine receptors, particularly A1 and A2A subtypes, play a crucial role in regulating various physiological processes, including neurotransmission, inflammation, and blood flow regulation. By modulating these receptors, N6-(6-Aminohexyl)-2’-deoxyadenosine could offer therapeutic benefits in conditions where adenosine signaling is dysregulated. For instance, studies have shown that selective adenosine receptor antagonists may have applications in treating cognitive disorders and improving cerebral blood flow in stroke patients.

Moreover, the compound's structural similarity to natural nucleosides makes it a valuable tool in synthetic biology and gene therapy. Nucleoside analogs are frequently used as substrates for DNA and RNA synthesis, enabling researchers to engineer novel nucleic acids with specific functionalities. N6-(6-Aminohexyl)-2’-deoxyadenosine could serve as a building block for creating custom nucleosides that exhibit enhanced stability or specific interactions with biological targets.

In clinical trials, N6-(6-Aminohexyl)-2’-deoxyadenosine has demonstrated promising results in preclinical models of cancer. By inhibiting adenosine-mediated tumor growth and angiogenesis, the compound may help suppress cancer progression. Additionally, its ability to cross the blood-brain barrier suggests potential applications in treating central nervous system disorders. Ongoing studies are exploring its efficacy in reducing neuroinflammation and protecting against neuronal damage in models of Alzheimer's disease and Parkinson's disease.

The synthesis of N6-(6-Aminohexyl)-2’-deoxyadenosine involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic techniques, such as solid-phase synthesis and chemoenzymatic methods, have been employed to optimize the production process. These advancements not only improve the scalability of the compound but also enhance its overall quality, making it suitable for rigorous scientific investigation.

From a regulatory perspective, N6-(6-Aminohexyl)-2’-deoxyadenosine is subject to standard guidelines for new chemical entities (NCEs) in pharmaceutical development. Compliance with Good Manufacturing Practices (GMP) ensures that the compound meets stringent quality standards for clinical use. Regulatory agencies continue to monitor its development closely to assess its safety and efficacy before approval for human trials.

The future prospects of N6-(6-Aminohexyl)-2’-deoxyadenosine are vast, with ongoing research expanding its potential applications across multiple therapeutic areas. Innovations in drug delivery systems, such as nanoparticles and liposomes, may further enhance its bioavailability and targeted action. Collaborative efforts between academia and industry are essential to translate these findings into tangible medical breakthroughs.

In conclusion, N6-(6-Aminohexyl)-2’-deoxyadenosine represents a significant contribution to nucleoside chemistry with far-reaching implications for biomedical research and drug development. Its unique structural features and diverse applications position it as a cornerstone in the quest for novel therapeutic agents that address some of today's most pressing medical challenges.

• 26293-51-6(Adenosine, N-pentyl-(8CI,9CI))
• 56934-06-6(Adenosine, N-(6-aminohexyl)-)
• 60687-66-3(Adenosine,N-(4-aminobutyl)-)
• 23096-10-8(Adenosine,N-butyl- (8CI,9CI))
• 111863-61-7(Adenosine,N,N''-1,6-hexanediylbis- (9CI))
• 111863-65-1(Adenosine,N,N''-1,12-dodecanediylbis- (9CI))
• 111863-62-8(Adenosine,N,N''-1,8-octanediylbis- (9CI))
• 111863-56-0(Adenosine,N-(8-aminooctyl)- (9CI))
• 15824-83-6(Adenosine, N-hexyl-(8CI,9CI))
• 869354-87-0(N6-[((((3-AMINOPROPOXY(ETHOXY))ETHOXY)ETHOXY)ETHOXY)-PROPYL]ADENOSINE)